Art

J-GLOBAL ID：201702232116717991   Reference number：17A0554444

ESMO2016でのCheckMate026とKEYNOTE-024のdiscrepancyとその理由~試験がみたのは薬か,人か~

Author (2)： HARATAKE NAOKI (九州がんセ 呼吸器腫瘍科) ,  SETO TAKASHI (九州がんセ 呼吸器腫瘍科)
Material： 月刊腫瘍内科  (腫瘍内科)
Volume： 19  Issue： 4  Page： 482-487  Publication year： Apr. 28, 2017 
JST Material Number： L6395A  ISSN： 1881-6568  Document type： Article
Article type： 解説  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *nivolumab ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0554444&from=J-GLOBAL&jstjournalNo=L6395A") }}

JST classification (3)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Tumors(=neoplasms)of respiratory system  (GI04000G)

Reference (11)：

• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016 ; 375: 1823.
• Socinski MA, Creelan B, Horn L, et al. NSCLC, metastaticCheckMate 026 : A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PTDC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1) - positive NSCLC. Ann Oncol 2016 ; 27 Suppl 6 : LBA7_PR.
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med 2012 ; 366 : 2455.
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015 ; 373: 123.
• Borghaei H, Paz-Ares L, Horncm L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015 ; 373: 1627.

Terms in the title (3)： 試験 ,  薬 ,  人